Charles River Laboratories Intl. Inc vs Datadog Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $288.87 (market cap $13.46B), while Datadog Inc trades at $240.18 (market cap $88.61B). The key difference: Datadog Inc is far larger — about 6.6× Charles River Laboratories Intl. Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Datadog Inc nearer its low. Which is the better fit depends on your goals.
| CRL | DDOG | |
|---|---|---|
Market Cap | $13.46B | $88.61B |
Sector | Health | Technology |
52-Week High | $282.00 | $288.15 |
52-Week Low | $145.57 | $102.62 |
Enterprise Value | $16.30B | $84.90B |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $284.37, up 2.66% today and near its 52-week high, reflecting strong bullish momentum. The stock has consistently beaten earnings estimates in recent quarters, including a Q2 2026 EPS of $3.02 versus $2.77 expected, and the company raised its full-year guidance. Despite negative net income margins, operating cash flow remains robust at $738 million in 2025. Analyst sentiment is overwhelmingly positive with 26 buy ratings and a consensus price target of $277.29.
The outlook is supported by improving biotech demand and cost controls, but high valuation multiples and recent insider selling pose risks. Earnings growth and margin expansion are key catalysts, though profitability challenges and macroeconomic sensitivity could pressure the stock. Investors should weigh strong technicals and analyst support against fundamental weaknesses and execution risks.
Datadog (DDOG) trades at $241.00, down 7.58% amid a bearish technical signal despite strong Q2 2026 earnings beats and raised full-year guidance. The stock shows elevated valuation ratios (P/E 493.56, P/S 22.83) but maintains robust revenue growth (36% YoY in Q2) and a high gross profit margin of 79.51%. Recent insider selling and mixed technical indicators contrast with an 83% analyst buy rating.
Outlook: Long-term growth driven by AI demand and net revenue retention above 120% supports upside to the $288.55 consensus target. Risks include valuation sensitivity, customer concentration, and execution pressure. The stock presents a growth opportunity with volatility near-term.
Trailing returns across standard periods
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Datadog is a cloud-native company that focuses on analyzing machine data. The firm's product portfolio, delivered as software-as-a-service, allows a client to monitor and analyze its entire IT infrastructure. Datadog's platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to utilize it for a variety of different applications throughout their businesses.
Read more on DDOG →